Katherine Bond

Katherine Bond

Auto-generated profile, based on publicly available information

Katherine Bond

Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
EWEloise Williams
Eloise Williams
KBKatherine Bond
Katherine Bond
BZBowen Zhang
Bowen Zhang
MPMark Putland
Mark Putland
DWDeborah A Williamson
Deborah A Williamson
Diagnostic testing for COVID-19 is central to controlling the global pandemic. …

1 April 2020 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
LCLeon Caly
Leon Caly
JDJulian Druce
Julian Druce
JRJason Roberts
Jason Roberts
KBKatherine Bond
Katherine Bond
TTThomas Tran
Thomas Tran
MCMike G Catton
Mike G Catton
Objectives To describe the first isolation and sequencing of SARS‐CoV‐2 in Australia and rapid sharing of the isolate. Setting SARS‐CoV‐2 was isolated from a 58‐year‐old man from Wuhan, China who ...

23 October 2015 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
KBK. A. Bond
K. A. Bond
GVG. Vincent
G. Vincent
CWC. R. Wilks
C. R. Wilks
LFL. Franklin
L. Franklin
BSB. Sutton
B. Sutton
SFSimon Firestone
Simon Firestone
SUMMARY: A recent outbreak of Q fever was linked to an intensive goat and sheep dairy farm in Victoria, Australia, 2012-2014. Seventeen employees and one family member were confirmed with Q fever over a 28-month period, including two culture-positive cases. The outbreak investigation and management involved a One Health approach with representation from human, animal, environmental and public health. Seroprevalence in non-pregnant milking goats was 15% [95% confidence interval (CI) 7–27]; active infection was confirmed by positive quantitative PCR on several animal specimens. Genotyping ofCoxiella burnetiiDNA obtained from goat and human specimens was identical by two typing methods. A number of farming practices probably contributed to the outbreak, with similar precipitating factors to the Netherlands outbreak, 2007-2012. Compared to workers in a high-efficiency particulate arrestance (HEPA) filtered factory, administrative staff in an unfiltered adjoining office and those regularly handling goats and kids had 5·49 (95% CI 1·29–23·4) and 5·65 (95% CI 1·09–29·3) times the risk of infection, respectively; suggesting factory workers were protected from windborne spread of organisms. Reduction in the incidence of human cases was achieved through an intensive human vaccination programme plus environmental and biosecurity interventions. Subsequent non-occupational acquisition of Q fever in the spouse of an employee, indicates that infection remains endemic in the goat herd, and remains a challenge to manage without source control.

1 October 2016 in Emerging Infectious Diseases
Verified
Journal Article
Open access
KCKylie S. Carville
Kylie S. Carville
KSKerrie Stevens
Kerrie Stevens
ASAsma Sohail
Asma Sohail
LFLucinda J. Franklin
Lucinda J. Franklin
KBKatherine A. Bond
Katherine A. Bond
KOKatherine S. Ong
Katherine S. Ong
In Victoria, Australia, invasive meningococcal disease caused by Neisseria meningitidis serogroup W increased from 4% of all cases in 2013 to 30% in 2015. This increase resulted largely from strains similar to those in the serogroup W sequence type 11 clonal complex, previously described in the United Kingdom and South America.

1 February 2021 in Journal of Medical Microbiology
Verified
Journal Article
Open access
EWEloise Williams
Eloise Williams
NINicole Isles
Nicole Isles
BCBrian Chong
Brian Chong
KBKatherine Bond
Katherine Bond
YYYano Yoga
Yano Yoga
DWDeborah A. Williamson
Deborah A. Williamson
Saliva has recently been proposed as a suitable specimen for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use of saliva as a diagnostic specimen may present opportunities for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing in remote and low-resource settings. Determining the stability of SARS-CoV-2 RNA in saliva over time is an important step in determining optimal storage and transport times. We undertook an in vitro study to assess whether SARS-CoV-2 could be detected in contrived saliva samples. The contrived saliva samples comprised 10 ml pooled saliva spiked with gamma-irradiated SARS-CoV-2 to achieve a concentration of 2.58×104 copies ml SARS-CoV-2, which was subsequently divided into 2 ml aliquots comprising: (i) neat saliva; and a 1 : 1 dilution with (ii) normal saline; (iii) viral transport media, and (iv) liquid Amies medium. Contrived samples were made in quadruplicate, with two samples of each stored at either: (i) room temperature or (ii) 4 °C. SARS-CoV-2 was detected in all SARS-CoV-2 spiked samples at time point 0, day 1, 3 and 7 at both storage temperatures using the N gene RT-PCR assay and time point 0, day 1 and day 7 using the Xpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, USA) RT-PCR assay. The ability to detect SARS-CoV-2 in saliva over a 1 week period is an important finding that presents further opportunities for saliva testing as a diagnostic specimen for the diagnosis of SARS-CoV-2.

12 September 2022 in Journal of Medical Microbiology
Verified
Journal Article
Open access
KYKim Yeoh
Kim Yeoh
MGMaria Globan
Maria Globan
PNPhillip Naimo
Phillip Naimo
DWDeborah A. Williamson
Deborah A. Williamson
KLKerrie Lea
Kerrie Lea
KBKatherine Bond
Katherine Bond
Introduction. Nocardia is an opportunistic pathogen that can cause significant morbidity and mortality, particularly in the immunocompromised host. Antimicrobial susceptibility profiles vary across Nocardia spp. and vary within Australia as well as worldwide. Knowledge of local susceptibility patterns is important in informing appropriate empiric antimicrobial therapy. Gap Statement. This is the largest study to date in Australia that correlates antimicrobial susceptibility profiles with molecular identification of Nocardia species. It is the first study that examines isolates from multiple institutions across the state of Victoria, Australia. Aim. To investigate the species distribution and antibiotic susceptibility of Nocardia spp. isolates referred to the Mycobacterial Reference Laboratory (MRL) in Victoria, Australia from 2009 to 2019. Methodology. We conducted a retrospective review of Nocardia spp. isolates which were identified using molecular sequencing. Antimicrobial susceptibility testing was performed using standardized broth microdilution method with Sensititre RAPMYCO1 plates. Species distribution and antibiotic susceptibility profiles were analysed. Results. In total, 414 Nocardia isolates were identified to 27 species levels, the majority originating from the respiratory tract (n=336, 81.2 %). N. nova (n=147, 35.5 %) was the most frequently isolated, followed by N. cyriacigeorgica (n=75, 18.1 %). Species distribution varied by isolate source, with N. farcinica and N. paucivorans found more commonly from sterile sites. Linezolid and amikacin had the highest proportion of susceptible isolates (100 and 99% respectively), while low susceptibility rates were detected for ceftriaxone (59 %) and imipenem (41 %). Susceptibility to trimethoprim sulfamethoxazole varied by species (0–100 %). Conclusion. This is the largest study to date in Australia of Nocardia species distribution and antimicrobial susceptibility patterns. N. farcinica and N. paucivorans were more likely to be isolated from sterile sites, while N. brasiliensis and N. otitidiscvarium were more likely to be isolated from skin and soft tissue. First line therapeutic antimicrobial recommendations by local guidelines were not necessarily reflective of the in vitro susceptibility of Nocardia isolates in this study, with high susceptibility detected for linezolid and amikacin, but poor susceptibility demonstrated for ceftriaxone and imipenem. Profiles for trimethoprim-sulfamethoxazole varied across different Nocardia species, warranting ongoing susceptibility testing for targeted clinical use.